Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023
BOULDER, Colo., Jan. 11, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced publication of data from preclinical studies of FRTX-02, a potential first-in-class, orally bioavailable DYRK1A inhibitor, in the Journal of Translational Autoimmunity. The paper shows FRTX-02 to be a potent and selective inhibitor of DYRK1A with the potential to restore immune homeostasis by regulating adaptive and innate immune system responses in models of various autoimmune and inflammatory diseases.
“We are excited to publish the results from several preclinical studies of FRTX-02 in animal models of psoriasis and atopic dermatitis,” commented Monica Luchi, M.D., Chief Medical Officer of Fresh Tracks. “These data provide preclinical characterization of FRTX-02 and evidence supporting its role in modulating chronic inflammatory and autoimmune responses, which helped pave the way for this drug candidate to enter a Phase 1 clinical trial in 2022. FRTX-02, to our knowledge, is the first and only clinical-stage, oral DYRK1A inhibitor being developed for patients with autoimmune diseases, and we look forward to reporting topline results from Part 1 (SAD and MAD) of the current Phase 1 study with FRTX-02 by the end of this quarter.”
Key preclinical findings as published in Journal of Translational Autoimmunity suggest the novel FRTX-02:
Attenuates inflammation in mouse models of atopic dermatitis and psoriasis, implying potential as a treatment for various autoimmune and inflammatory diseases;
Restores the adaptive immune system through promotion of Treg differentiation and suppression of pro-inflammatory Th17 and Th1 differentiation;
Induces alternative splicing of myeloid differentiation primary response 88 (MyD88), thereby regulating the innate immune system by blocking Interleukin-1 receptor-associated kinase 4 (IRAK4) phosphorylation; and
Has the potential to restore immune homeostasis, presenting a novel approach to regulating adaptive and innate inflammatory immune responses.
A link to the publication titled, “FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis” may be found online here.
FRTX-02 is a potent, highly selective, and orally bioavailable potential first-in-class dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor that is currently being evaluated in a first-in-human Phase 1 clinical trial (topline results expected in the first quarter of 2023) and has shown promising results in various preclinical models, including of atopic dermatitis and rheumatoid arthritis. In these preclinical models, decreases in disease severity and reduction of pro-inflammatory cytokines were reported compared to certain current standard-of-care agents, such as Janus kinase (JAK) inhibitors and anti-tumor necrosis factor (TNF) biologics. Notably, many current therapies for autoimmune disorders are broadly immunosuppressant, which may lead to severe side effects, such as increased infection risk. Preclinical data suggest that FRTX-02 may drive regulatory T cell differentiation while dampening pro-inflammatory T helper cells and MyD88/IRAK4-related signaling pathways. Regulatory T cells serve to maintain tolerance and keep the autoreactive, pro-inflammatory T cells in check, thus decreasing the likelihood of autoimmune disease and limiting chronic inflammation. The MyD88 protein is normally spliced into a long form and a short form. The long form of MyD88 drives inflammation via pathways related to IRAK4, a protein kinase involved in signaling immune responses from toll-like receptors, while the short form of MyD88 limits IRAK4 phosphorylation and its respective downstream signaling pathway. DYRK1A inhibition shifts the balance to produce more MyD88 short form, which leads to deactivation of the downstream release of several pro-inflammatory cytokines. Based on current understanding, inhibition of this release of excess cytokines can be achieved by re-establishing the role of MyD88 short form as a negative regulator of this pathway. Unlike many existing therapies for autoimmune diseases, as well as the majority of those currently being investigated, FRTX-02 may have the ability to target both the adaptive and innate immune imbalance simultaneously, potentially resulting in, or substantially achieving, restoration of immune homeostasis that, if proven, would represent a paradigm shift in the treatment of certain autoimmune and inflammatory diseases.
About Fresh Tracks Therapeutics
Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new chemical entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Tracks’ executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products, some of which have achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and sofpironium bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases. For more information, visit https://www.frtx.com/.
Cautionary Note Regarding Forward-Looking Statements
Any statements made in this press release relating to future financial, business, and/or research and development, investigational, preclinical, or clinical performance and potential, conditions, plans, prospects, impacts, shifts, trends, or strategies and other such matters, including without limitation, Fresh Tracks’ strategy; future operations; future potential; future financial position; future liquidity; future revenue; territorial focus; projected expenses; results of operations; the anticipated timing, scope, design, progress, results, possible impact of, and/or reporting of data of ongoing and future nonclinical and clinical trials involving FRTX-02 and any other products; intellectual property rights, including the acquisition, validity, term, and enforceability of such; the expected timing and/or results of regulatory submissions and approvals; and prospects for treatment of patients and commercializing (and competing with) any product candidates for any disease by Fresh Tracks or third parties, or research and/or licensing collaborations with, or actions of, its partners, including in the United States, Japan, South Korea, or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “might,” “announce,” “anticipate,” “advancing,” “reflect,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “will,” “evaluate,” “advance,” “excited,” “aim,” “strive,” “help,” “progress,” “select,” “initiate,” “look forward,” “promise,” “provide,” “commit,” “best-in-class,” “first-in-class,” “standard-of-care,” “on track,” “opportunity,” “disrupt,” “restore,” “suggest,” “attenuate,” “imply,” “induce,” “regulates,” “dampens,” “targets,” “shift,” and similar expressions and their variants, as they relate to Fresh Tracks or any of Fresh Tracks’ investigational products, partners, or third parties, may identify forward-looking statements. Fresh Tracks cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly, and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, research results and data that do not meet targets, expectations or regulatory approval requirements; ability to obtain adequate financing for product development, regulatory submissions, and any commercialization; ability to acquire, maintain and enforce intellectual property rights; potential delays or alterations in product development, trials of any type, and regulatory submission and reviews; changes in law or policy; litigation, regulatory agency actions, feedback, or requests; supply chain disruptions; unanticipated demands on cash resources; disruptions and negative effects related to the COVID-19 pandemic and the conflict in Ukraine; interruptions, disruption, or inability by Fresh Tracks, its partners or third parties to obtain or supply research material, raw materials, and/or product anywhere, or secure essential services, in the world; efforts to obtain and retain adequate pricing and adequate reimbursement and other insurance coverage for Fresh Tracks’ future products; the outcome of and reaction to Fresh Tracks’ current and planned preclinical and clinical trials across its portfolio of assets; the inability of third parties to achieve the regulatory and sales-based events under Fresh Tracks’ agreements with them, or their lack of funds, resulting in Fresh Tracks not receiving additional or full payments due from them; and other risks associated with (i) developing and obtaining regulatory approval for, and commercializing, product candidates, (ii) raising additional capital, and (iii) maintaining compliance with Nasdaq listing requirements.
Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Fresh Tracks’ filings with the United States Securities and Exchange Commission, which are available at https://www.sec.gov (or at https://www.frtx.com). The forward-looking statements represent the estimates of Fresh Tracks as of the date hereof only. Fresh Tracks specifically disclaims any duty or obligation to update forward-looking statements.
FRTX Investor Contact:
Investors in marijuana stocks such as Aurora Cannabis (NASDAQ: ACB), Tilray (NASDAQ: TLRY), and Curaleaf (OTC: CURLF) are having a good day today — their first after four days of nonstop selling for some of these stocks. Through 12:12 p.m. ET on Wednesday, shares of Curaleaf are gaining 1.3%, and Aurora Cannabis is up 2.6%, while Tilray stock is leading the whole sector higher with a big 6% gain. The growing popularity of medical marijuana apparently is behind it all.
Is Pfizer stock a buy or a sell after getting a downgrade on its falling Covid-tied sales? Is PFE stock a buy or a sell right now?
Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi
The new CEO of Karuna Therapeutics Inc. has big plans in mind for KarXT, the company's novel schizophrenia drug.
The highly transmissible 'Kraken' COVID variant is here. Experts say getting boosted is your best protection.
The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.
My Motley Fool colleague Sean Williams even predicts that it will be the year's top-performing sector. Here are three top healthcare stocks to buy for January. Vertex also is moving forward with early-stage clinical testing of VX-522.
You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu. The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY), received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) last week. Biogen has been in this position before.
Nora Boydstun is diligent about checking expiration dates.
Is Moderna stock a buy or a sell after issuing a light preliminary sales outlook for 2022? Is MRNA stock a buy or sell right now?
The SPDR S&P Biotech ETF is down 20% over the past year. In fact, BioMarin Pharmaceuticals (NASDAQ: BMRN) and Novo Nordisk (NYSE: NVO) are at their highest levels in a year. The company was founded in 1997 to develop treatments for extremely rare genetic diseases.
While Biogen's new CEO says he isn't planning any "radical left turns," he does see some ways the company could tap into new markets, including immunology and rare diseases.
AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.
"We are confident that Damar can be safely discharged to continue his rehabilitation at home and with the Bills," his medical team in Buffalo said.View Entire Post ›
Yahoo Finance Live anchors discuss the U.S. Consumer Product Safety Commission reviewing gas stoves and range tops amid respiratory and certain cancer risks linked to use.
Health board chiefs in Scotland have suspended non-emergency operations and ordered GPs to only see urgent patients after Nicola Sturgeon said mass cancellations would be permitted.
Sutro Biopharma Inc (NASDAQ: STRO) announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta) and interim safety data from exploratory cohort C of advanced ovarian cancer treated at the higher dose of luvelta (5.2mg/kg), along with prophylactic pegfilgrastim. Results demonstrated that luvelta provided substantial clinical benefit, with a 37.5% overall response rate (ORR), a median duration of response (median DOR) of 5.5 months, and median progression-free survival (median PFS)
Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company.
Jaguar Health, Inc. (NASDAQ: JAGX), Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) and One Small Planet, LLC today announced the formation of a U.S.-based joint venture named Magdalena Biosciences, Inc. to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. Initial funding of US$1,000,000 will be invested by Boulder, Colorado-based One Small Planet, founded by Will Peterffy. This fund
The Botanist in Montville and Fine Fettle Dispensary in Willimantic among Connecticut shops selling adult-use cannabis the first day sales are legal.